Another batch of high priced anticancer drugs may be on sale in April! Industry: innovative R & D is still the key

[pharmaceutical network industry trends] "before, drugs were there, but they couldn't be bought Later, the medicine was still there, but it couldn't be bought " Expensive anti-cancer drugs can be reimbursed, which gives hope to people suffering from terminal diseases It is understood that expensive medical treatment has been an old problem for many years In 2019, China made a breakthrough in reducing the burden of medical treatment for the masses Taking Shandong Province as an example, all 16 cities have set up a drug consumables procurement consortium and started the joint volume procurement work, achieving the goal of reducing the price and the same price in the same city It is reported that this year, Shandong Medical Insurance Bureau will implement the results of the second batch of purchasing with volume organized by the state The second batch of 33 drugs, including common drugs such as antidiabetic drugs, antihypertensive drugs, antibiotics, and some high-priced anticancer drugs and rare disease drugs, will soon have the result of price reduction, and is expected to be implemented in Shandong Province in April Anticancer drugs enter the medical insurance catalog, which makes many patients feel better However, in order to solve the problem of anticancer drugs from the source, we need to continue to carry out pharmaceutical innovation The author has learned that in recent years, China has continuously introduced favorable policies to encourage the development of innovative drugs In the past two years, the number of new drug approvals in the Chinese market has increased dramatically, and it is expected that more global new drugs will be approved in the future For example, in 2018, about 35 new drugs were approved as a result of favorable policies, including 14 anti-tumor drugs Lenvatinib (lovatinib), a thyroid cancer treatment drug, was approved 9 days after its application Eight of the 14 approved new anticancer drugs are innovative drugs developed locally The industry said that although there is still a big gap between the domestic anti-cancer drug market and the developed countries, the growth prospects are considerable Data shows that in 2018, China's tumor treatment market reached about 9 billion US dollars, an annual growth of 11.1% Tumor drugs increased by 23.6% to US $6.3 billion With the acceleration of review and approval and the promotion of other favorable policies, some pharmaceutical enterprises in China have begun to strengthen the research and development of anti-cancer drugs For example, in the evening of January 16, Fosun Pharmaceutical released a notice that the orin1001 tablet developed by Fosun hongchuang (Suzhou) Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Fosun hongchuang"), a holding subsidiary of the company, was approved for clinical trials for the treatment of advanced solid tumors It is reported that in January this year, including orin1001 tablets, Fosun Group has two new anti-cancer drugs approved for clinical use, the other is fcn-647 capsule, which is used for the treatment of recurrent or refractory lymphocytic malignant tumors, and it is also an innovative small molecule drug independently developed According to the data of the semi annual report of 2019 released by the company, the group has 233 projects in research and development of new drugs, generic drugs, biological similar drugs and generic drug consistency evaluation Among them, there are 16 small molecule innovative drugs, 12 biological innovative drugs and 20 biological similar drugs   Fortunately, through the continuous efforts of enterprises, good news is also coming out in the field of anticancer drugs In addition to the above enterprises, on December 28, 2019, Baiji Shenzhou announced that the independently developed anti-PD-1 antibody drug baizean (commonly known as tirelizumab injection) has been officially approved by the National Drug Administration (nmpa) for treatment at least through the second-line system Patients with relapsed or refractory classical Hodgkin's lymphoma (R / rchl) after chemotherapy The industry said that with the reform of the national medical policy and system, as well as the strong support for the creation of new drugs, the domestic pharmaceutical industry is undergoing tremendous changes, and the era of cancer immunotherapy belonging to China is coming 2019 is also a year of accelerated drug review and approval The new drugs approved by nmpa in 2019 cover cancer, rare diseases, diabetes, antiviral drugs such as hepatitis C, influenza, immunology, nervous system and many other treatment fields, with many highlights I believe that with the coming of 2020, there will be more good news in the field of anti-cancer drugs and other new drugs in China.